The global influenza vaccination market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth in this market is attributed to the increasing number of people suffering from chronic diseases and respiratory disorders, which are major risk factors for contracting influenza. The increasing awareness about the benefits of vaccination among healthcare professionals and patients is also driving the growth in this market.
The egg-based segment accounted for a share of over 50% in 2018 and is expected to maintain its dominance throughout the forecast period owing to its low cost and ease of production. However, cell culture segment will witness significant growth due to its higher efficacy rates as compared with egg-based vaccines.
Some Of The Growth Factors Of This Market:
- Influenza is a highly contagious respiratory illness that can lead to serious complications, such as pneumonia and death.
- The Centers for Disease Control and Prevention (CDC) recommends annual influenza vaccination for everyone 6 months of age or older, including pregnant women.
- Influenza vaccine is safe and effective in preventing the flu in healthy adults and children 2 years of age or older, as well as in people with certain chronic medical conditions like asthma, diabetes mellitus, heart disease, kidney disease, liver disease (cirrhosis), neurological disorders (such as multiple sclerosis), anemia from any cause other than blood loss or cancer chemotherapy; people who are immunosuppressed due to HIV infection or receiving long-term steroids; people 65 years of age or older; children 6 months through 8 years old who have chronic health problems such as asthma; pregnant women during any trimester of pregnancy; household contacts and caregivers of children less than 6 months old if they have not previously been vaccinated against influenza this season.
- Influenza vaccine is available in both injectable form (shot) and nasal spray form.
- The CDC recommends that all persons aged six months or more should receive an annual influenza vaccination.
Industry Growth Insights published a new data on “Influenza Vaccination Market”. The research report is titled “Influenza Vaccination Market research by Types (Egg Based, Cell Culture, Recombinant), By Applications (Hospitals, Research Organizations), By Players/Companies Abbott (U.S.), AstraZeneca (Europe), BioCryst Pharmaceuticals, Inc. (U.S.), Novartis AG (Europe), DAIICHI SANKYO COMPANY, LIMITED. (Asia Pacific), GlaxoSmithKline plc. (Europe), Hualan Biological Engineering Inc (Asia Pacific), Mitsubishi Tanabe Pharma Corporation (Asia Pacific), F. Hoffmann-La Roche Ltd (Europe), Sanofi (Europe)”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Influenza Vaccination Market Research Report
By Type
Egg Based, Cell Culture, Recombinant
By Application
Hospitals, Research Organizations
By Companies
Abbott (U.S.), AstraZeneca (Europe), BioCryst Pharmaceuticals, Inc. (U.S.), Novartis AG (Europe), DAIICHI SANKYO COMPANY, LIMITED. (Asia Pacific), GlaxoSmithKline plc. (Europe), Hualan Biological Engineering Inc (Asia Pacific), Mitsubishi Tanabe Pharma Corporation (Asia Pacific), F. Hoffmann-La Roche Ltd (Europe), Sanofi (Europe)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Influenza Vaccination Market Report Segments:
The global Influenza Vaccination market is segmented on the basis of:
Types
Egg Based, Cell Culture, Recombinant
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Research Organizations
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott (U.S.)
- AstraZeneca (Europe)
- BioCryst Pharmaceuticals, Inc. (U.S.)
- Novartis AG (Europe)
- DAIICHI SANKYO COMPANY, LIMITED. (Asia Pacific)
- GlaxoSmithKline plc. (Europe)
- Hualan Biological Engineering Inc (Asia Pacific)
- Mitsubishi Tanabe Pharma Corporation (Asia Pacific)
- F. Hoffmann-La Roche Ltd (Europe)
- Sanofi (Europe)
Highlights of The Influenza Vaccination Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Egg Based
- Cell Culture
- Recombinant
- By Application:
- Hospitals
- Research Organizations
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Influenza Vaccination Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Influenza vaccination is a vaccine that helps protect people from the flu. It is recommended for everyone 6 months of age and older, including pregnant women. The Centers for Disease Control and Prevention (CDC) recommends annual influenza vaccination for all Americans, especially those at high risk.
Some of the major players in the influenza vaccination market are Abbott (U.S.), AstraZeneca (Europe), BioCryst Pharmaceuticals, Inc. (U.S.), Novartis AG (Europe), DAIICHI SANKYO COMPANY, LIMITED. (Asia Pacific), GlaxoSmithKline plc. (Europe), Hualan Biological Engineering Inc (Asia Pacific), Mitsubishi Tanabe Pharma Corporation (Asia Pacific), F. Hoffmann-La Roche Ltd (Europe), Sanofi (Europe).
The influenza vaccination market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Influenza Vaccination Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Influenza Vaccination Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Influenza Vaccination Market - Supply Chain
4.5. Global Influenza Vaccination Market Forecast
4.5.1. Influenza Vaccination Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Influenza Vaccination Market Size (000 Units) and Y-o-Y Growth
4.5.3. Influenza Vaccination Market Absolute $ Opportunity
5. Global Influenza Vaccination Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Influenza Vaccination Market Size and Volume Forecast by Type
5.3.1. Egg Based
5.3.2. Cell Culture
5.3.3. Recombinant
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Influenza Vaccination Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Influenza Vaccination Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Research Organizations
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Influenza Vaccination Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Influenza Vaccination Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Influenza Vaccination Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Influenza Vaccination Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Influenza Vaccination Demand Share Forecast, 2019-2026
9. North America Influenza Vaccination Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Influenza Vaccination Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Influenza Vaccination Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Research Organizations
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Influenza Vaccination Market Size and Volume Forecast by Type
9.7.1. Egg Based
9.7.2. Cell Culture
9.7.3. Recombinant
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Influenza Vaccination Demand Share Forecast, 2019-2026
10. Latin America Influenza Vaccination Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Influenza Vaccination Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Influenza Vaccination Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Research Organizations
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Influenza Vaccination Market Size and Volume Forecast by Type
10.7.1. Egg Based
10.7.2. Cell Culture
10.7.3. Recombinant
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Influenza Vaccination Demand Share Forecast, 2019-2026
11. Europe Influenza Vaccination Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Influenza Vaccination Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Influenza Vaccination Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Research Organizations
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Influenza Vaccination Market Size and Volume Forecast by Type
11.7.1. Egg Based
11.7.2. Cell Culture
11.7.3. Recombinant
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. y Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Influenza Vaccination Demand Share, 2019-2026
12. Asia Pacific Influenza Vaccination Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Influenza Vaccination Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Influenza Vaccination Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Research Organizations
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Influenza Vaccination Market Size and Volume Forecast by Type
12.7.1. Egg Based
12.7.2. Cell Culture
12.7.3. Recombinant
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Influenza Vaccination Demand Share, 2019-2026
13. Middle East & Africa Influenza Vaccination Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Influenza Vaccination Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Influenza Vaccination Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Research Organizations
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Influenza Vaccination Market Size and Volume Forecast by Type
13.7.1. Egg Based
13.7.2. Cell Culture
13.7.3. Recombinant
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Influenza Vaccination Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Influenza Vaccination Market: Market Share Analysis
14.2. Influenza Vaccination Distributors and Customers
14.3. Influenza Vaccination Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Abbott (U.S.)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AstraZeneca (Europe)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. BioCryst Pharmaceuticals, Inc. (U.S.)
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis AG (Europe)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. DAIICHI SANKYO COMPANY, LIMITED. (Asia Pacific)
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. GlaxoSmithKline plc. (Europe)
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Hualan Biological Engineering Inc (Asia Pacific)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Mitsubishi Tanabe Pharma Corporation (Asia Pacific)
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. F. Hoffmann-La Roche Ltd (Europe)
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Sanofi (Europe)
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
